5 research outputs found
Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors
Src
homology 2-containing protein tyrosine phosphatase 2 (SHP2)
is the first reported nonreceptor oncogenic tyrosine phosphatase connecting
multiple signal transduction cascades and exerting immunoinhibitory
function through the PD-1 checkpoint receptor. As part of a drug discovery
program aimed at obtaining novel allosteric SHP2 inhibitors, a series
of pyrazopyrazine derivatives bearing an original bicyclo[3.1.0]hexane
basic moiety on the left-hand side region of the molecule were identified.
We report herein the discovery process, the in vitro pharmacological
profile, and the early developability features of compound 25, one of the most potent members of the series
Discovery of 1‑(1<i>H</i>‑Pyrazolo[4,3‑<i>c</i>]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers
The ERK/MAPK pathway
plays a central role in the regulation of
critical cellular processes and is activated in more than 30% of human
cancers. Specific BRAF and MEK inhibitors have shown clinical efficacy
in patients for the treatment of BRAF-mutant melanoma. However, the
majority of responses are transient, and resistance is often associated
with pathway reactivation of the ERK signal pathway. Acquired resistance
to these agents has led to greater interest in ERK, a downstream target
of the MAPK pathway. De novo design efforts of a novel scaffold derived
from SCH772984 by employing hydrogen bond interactions specific for
ERK in the binding pocket identified 1-(1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)ureas as a viable lead series. Sequential
SAR studies led to the identification of highly potent and selective
ERK inhibitors with low molecular weight and high LE. Compound <b>21</b> exhibited potent target engagement and strong tumor regression
in the BRAF<sup>V600E</sup> xenograft model
Discovery of 1‑(1<i>H</i>‑Pyrazolo[4,3‑<i>c</i>]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers
The ERK/MAPK pathway
plays a central role in the regulation of
critical cellular processes and is activated in more than 30% of human
cancers. Specific BRAF and MEK inhibitors have shown clinical efficacy
in patients for the treatment of BRAF-mutant melanoma. However, the
majority of responses are transient, and resistance is often associated
with pathway reactivation of the ERK signal pathway. Acquired resistance
to these agents has led to greater interest in ERK, a downstream target
of the MAPK pathway. De novo design efforts of a novel scaffold derived
from SCH772984 by employing hydrogen bond interactions specific for
ERK in the binding pocket identified 1-(1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-yl)ureas as a viable lead series. Sequential
SAR studies led to the identification of highly potent and selective
ERK inhibitors with low molecular weight and high LE. Compound <b>21</b> exhibited potent target engagement and strong tumor regression
in the BRAF<sup>V600E</sup> xenograft model
Recommended from our members
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor
The bromodomain containing proteins
TRIM24 (tripartite motif containing
protein 24) and BRPF1 (bromodomain and PHD finger containing protein
1) are involved in the epigenetic regulation of gene expression and
have been implicated in human cancer. Overexpression of TRIM24 correlates
with poor patient prognosis, and BRPF1 is a scaffolding protein required
for the assembly of histone acetyltransferase complexes, where the
gene of MOZ (monocytic leukemia zinc finger protein) was first identified
as a recurrent fusion partner in leukemia patients (8p11 chromosomal
rearrangements). Here, we present the structure guided development
of a series of <i>N</i>,<i>N</i>-dimethylbenzimidazolone
bromodomain inhibitors through the iterative use of X-ray cocrystal
structures. A unique binding mode enabled the design of a potent and
selective inhibitor <b>8i</b> (IACS-9571) with low nanomolar
affinities for TRIM24 and BRPF1 (ITC <i>K</i><sub>d</sub> = 31 nM and ITC <i>K</i><sub>d</sub> = 14 nM, respectively).
With its excellent cellular potency (EC<sub>50</sub> = 50 nM) and
favorable pharmacokinetic properties (<i>F</i> = 29%), <b>8i</b> is a high-quality chemical probe for the evaluation of
TRIM24 and/or BRPF1 bromodomain function in vitro and in vivo
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
A new class of HCV NS3/4a protease inhibitors containing
a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds
and exploring the P2 and linker regions of the series allowed for
optimization of broad genotype and mutant enzyme potency, cellular
activity, and rat liver exposure following oral dosing. These studies
led to the identification of clinical candidate <b>15</b> (MK-5172),
which is active against genotype 1–3 NS3/4a and clinically
relevant mutant enzymes and has good plasma exposure and excellent
liver exposure in multiple species